Patients with mHSPC benefited from darolutamide + ADT + docetaxel irrespective of age (<75 years and ≥75 years), with consistent improvements in overall survival, time to mCRPC, and time to initiation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback